The BioPharm Brief: Biosimilars, Stem Cells, and Checkpoints

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today's briefing highlights progress in biosimilars, cell therapy manufacturing, and cancer immunotherapy, underscoring how companies and researchers are working to expand patient access, streamline development, and tackle some of oncology's toughest challenges.

First, Lupin announced that the FDA has approved Ranluspec, an interchangeable biosimilar to Lucentis, for multiple retinal diseases. The product is approved in both vial and prefilled syringe presentations and covers indications including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion-related macular edema. The approval adds another competitor to the ophthalmology biosimilars market and reflects continued momentum in efforts to improve access to high-cost biologic therapies.

Next, cell therapy manufacturing received a boost through a new partnership between Made Scientific and Pluristyx. The companies plan to integrate Pluristyx's clinical-grade induced pluripotent stem cell, or iPSC, technologies into Made Scientific's development and manufacturing services. The goal is to provide developers with a more streamlined path from starting cell lines through clinical and commercial production, potentially reducing development timelines and manufacturing complexity for next generation cell therapies.

Finally, a newly published review examined TIGIT, an immune checkpoint target that continues to attract attention despite mixed clinical results. Researchers highlighted TIGIT's role in regulating antitumor immune responses and discussed its potential relevance in pancreatic cancer, a disease where immunotherapy has historically delivered limited benefit. The review emphasizes that important questions remain regarding patient selection, biomarkers, combination strategies, and whether TIGIT inhibition can generate meaningful clinical benefit in difficult-to-treat solid tumors.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

• Ranluspec approved: FDA approval of Lupin's interchangeable ranibizumab biosimilar expands competition in the retinal disease market.
• iPSC partnership launched: Made Scientific and Pluristyx aim to streamline development and manufacturing for iPSC-derived cell therapies.
• TIGIT questions remain: New research highlights TIGIT's potential in cancer immunotherapy, but clinical validation is still needed.